Results 91 to 100 of about 15,288 (159)

Paradoxical Effect of Obesity on Survival Outcomes in Prostate Cancer Patients Receiving Enzalutamide and Abiraterone. [PDF]

Medicina (Kaunas)
Kaya BE, Koçak MZ, Yıldız O, Aykut T, Gürbüz AF, Genç Ö, Karakurt Eryılmaz M, Araz M, Artaç M.   +8 more
europepmc   +1 more source

Sex Matters: Hormonal and Chromosomal Determinants of Autoimmunity and Anti‐Cancer Immunity Across the Lifespan

Immunological Reviews, Volume 338, Issue 1, March 2026.
ABSTRACT Sex plays a key role in shaping both anti‐cancer immunity and autoimmunity. Biological factors underlying sexual dimorphism have now been identified in multiple aspects of anti‐cancer immunity and autoimmunity. These factors include sex differences in hormone levels, chromosome complement, and expression of the long non‐coding RNA XIST.
Christian G. Bustillos, Esther M. Peluso, Sophia L. Cha, Melissa G. Lechner, Maureen A. Su   +4 more
wiley   +1 more source

Prognostic Factors of Castration-Resistant Prostate Cancer Among Patients With Localized Prostate Cancer Who Underwent Robot-Assisted Radical Prostatectomy in a Retrospective Multicenter Japanese Cohort (MSUG94). [PDF]

Int J Urol
Sasaki T, Igarashi A, Ebara S, Tatenuma T, Ikehata Y, Nakayama A, Kawase M, Toide M, Yoneda T, Sakaguchi K, Teishima J, Makiyama K, Kitamura H, Saito K, Koie T, Koga F, Urakami S, Yamasaki T, Inoue T.   +18 more
europepmc   +1 more source

Sex Differences in Cancer Immunotherapy—Clinical Evidence and Mechanisms With a Focus on NSCLC

Immunological Reviews, Volume 338, Issue 1, March 2026.
ABSTRACT Accumulating evidence suggests that the immune system shows subtle but relevant differences between men and women. These differences may have an impact on cancer development and TME composition as well as responses to and adverse events elicited by immunotherapies.
Eva Krieghoff‐Henning, Balagopal Pai, Maike Collienne, Isabel Ben‐Batalla, Sonja Loges   +4 more
wiley   +1 more source

Two Cases of Metastatic Castration-Resistant Prostate Cancer With Long-Term Survival Treated With Abiraterone. [PDF]

Clin Case Rep
Une M, Yamamoto S, Fuse H, Fujiwara R, Yonese J, Noda K.   +5 more
europepmc   +1 more source

ODC1 Polyamine Metabolism Drives Prostate Cancer via AKT and Splicing

Journal of Cellular and Molecular Medicine, Volume 30, Issue 5, March 2026.
ABSTRACT Prostate cancer is an aggressive disease with limited quantifiable biomarkers. One gene of interest is ODC1, which encodes ornithine decarboxylase, the rate‐limiting enzyme converting ornithine to putrescine in polyamine metabolism. Although ODC1 is known to be involved in prostate cancer development, exactly how it drives the disease ...
Jian Ma, Ting Pan, Shengli Sun, Musitapa Mutalifu, Wei Yang, Yue Niu, Peng Chen   +6 more
wiley   +1 more source

Treatment-related changes in the prostate: past, present and future therapies. [PDF]

Histopathology
Collins K, Cheng L.
europepmc   +1 more source

Survival after spinal surgery for metastases in men with castration-sensitive vs castration-resistant prostate cancer: a nationwide register-based study. [PDF]

Sci Rep
Wänman J, Farhang M, Nyström H, Styrke J, Häggström C, Stattin P, Crnalic S.   +6 more
europepmc   +1 more source

Efficacy and toxicity of low-doses versus standard-dose enzalutamide in advanced prostate cancer: a real-world study with implications for cancer prevention/interception. [PDF]

BMC Cancer
Oliva M, Boitano M, Carbone A, Briata IM, Webber TB, Corradengo D, Introini C, Puntoni M, Ennas M, Germinale F, Provinciali N, Clavarezza M, Gozza A, Defferrari C, D'Amico M, Parnes HL, DeCensi A.   +16 more
europepmc   +1 more source

The Role of Nuclear Medicine in Prostate Cancer. [PDF]

Diagnostics (Basel)
Grozdic Milojevic I, Milojevic B, Skrijelj D, Bumbasirevic U, Janicic A, Kajmakovic B, Sobic-Saranovic D, Artiko V, Beatovic S.   +8 more
europepmc   +1 more source